Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is poised to continue its strong financial performance and growth as it expands its global presence in the medical aesthetics market through its highly effective and innovative brands, including Hydrafacial and SkinStylus. With a solid balance sheet and increasing profitability, the company is well-positioned to address any long-term debt maturities and invest in new product development to drive future growth. However, potential risks include ongoing challenges in converting profitability into free cash flow and intensifying competition in the aesthetics landscape.

Bears say

SkinHealth Systems is facing a number of fundamental challenges including a decline in revenue due to capital constraints, weaker utilization of consumables, and a lower active install base. In addition, the company's significant convertible debt maturity in 2028 poses a long-term balance-sheet overhang. While the company is taking measures to address these issues, there are still risks of lower consumer demand and market share loss, as well as the potential for patent expiration and challenges in maintaining its brand reputation. These challenges, along with a slower-than-expected recovery in sales, lead to a negative outlook on the stock.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.